Navigation Links
Helix BioPharma Announces Q2 2009 Financial Results
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second quarter of fiscal 2009, ended January 31, 2009.

RECENT HIGHLIGHTS

  • Helix filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission which became effective on March 12, 2009

  • Helix received regulatory approval to commence a small European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials

  • Dr. Chao presented L-DOS47's mechanism of action at the Second Conference of Lung Cancer in Warsaw, Poland.

Results from Operations

Three and six month periods ended January 31, 2009 compared to the same periods in the previous year

Loss for the period

The Company recorded a loss of $4,252,000 and $6,573,000, respectively, for the three and six month periods ended January 31, 2009, for a loss per common share of $0.08 and $0.13, respectively. In the comparative three and six month periods ended January 31, 2008, the Company recorded a loss of $1,526,000 and $3,170,000, respectively, for a loss per common share of $0.04 and $0.08, respectively.

Revenues

Total revenues for the three month period ended January 31, 2009 totaled $863,000 (2008 - $791,000), resulting in an increase of $72,000 or 9.1%. Total revenues, for the six month period ended January 31, 2009 totaled $1,982,000 (2008 - $1,676,000), resulting in an increase of $306,000 or 18.3%.

Product Revenue

Product revenue totaled $740,000 and $1,661,000 respectively for the three and six month periods ended January 31, 2009 and represent an increase of $88,000 (13.5%
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... drug candidates targeting specific pathogens that cause serious ... its final preclinical toxicology study of SYN-004. Per ... bridging study was required to move the Company,s ... the devastating effects of Clostridium difficile (C. ...
(Date:9/2/2014)... 2, 2014 Culot brings life ... lab management services  BioData, producer of Labguru, ... to announce the appointment of Louis Culot ... as VP Marketing and Business Development at BioDiscovery Inc., ... clinical applications. Previously, Culot worked for 17 ...
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
(Date:8/31/2014)... August 31, 2014 This is ... state of the Epoxy Hardener industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... MEDdevice Acquisition Co., LLC,MDAC is proud to announce that ... experience and proven success optimizing investments in,the medical device ... announced include:, Tony Dimun, CEO of Nascent Enterprises, ... Larry Gold, PhD, Chairman and CEO of SomaLogic ...
... May 14 Biodel Inc. (Nasdaq:,BIOD) today announced that ... and Treasurer of Biodel, will present a,corporate update at ... May 22, 2008 at 1:00 p.m. Eastern Time. The,conference ... New York, New York., Interested parties may access ...
... Company employees in nearly 50 nations are rolling up ... celebration of Lilly,s,first-ever Global Day of Service, possibly the ... day., Beginning at sunrise in New Zealand, Lilly ... energy to improve the health and,well-being of communities around ...
Cached Biology Technology:MEDdevice Acquisition Co., LLC Announces Board Members and Advisors 2Lilly Employees from Nearly 50 Nations Participate in Company's First-Ever Global Day of Service 2
(Date:8/29/2014)... some surprising discoveries about the body,s initial responses ... the team found that specialized cells in the ... viral invasion and are the source of gut ... (IL-1β). , Though aimed at the presence ... epithelium that provides a barrier to protect the ...
(Date:8/29/2014)... over the last 120,000 years may have influenced ... researchers led by City College of New York ... metric called "phylogeographic endemism." , It quantifies the ... is restricted in geographical space. , Dr. Carnaval, ... researchers from institutions in Brazil, Australia and the ...
(Date:8/29/2014)... prolific bloomer Emiliania huxleyi , can grow without ... contradicts the common view that E. huxleyi ... of thiamine in the ocean to survive. , "It,s ... says CIFAR Senior Fellow Alexandra Worden , co-author ... fellows John Archibald (Dalhousie University), Adrin ...
Breaking Biology News(10 mins):The early cost of HIV 2CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... Fingerprinting for Kids" event on April 18 at ... CHESAPEAKE, Va., April 2 Turner Network Sales ... System, Inc. (TBS, Inc.), and truTV, are partnering with Cox ... "Digital Fingerprinting for Kids" event , a service designed ...
... Wins Gold Innovation Award; Senior Scientist Dr. Caleb ... Receives Certificate of RecognitionBOSTON, April 6 ... revolutionary biometric media research firm specializing in Emotional ... Awards from the Advertising Research Foundation.The Innovation Awards, ...
... Aware, Inc. (Nasdaq: AWRE ), a ... announced the preliminary results of its modified Dutch Auction ... City time, on Friday, April 17, 2009.In accordance with ... based on the preliminary count by Computershare Trust Company, ...
Cached Biology News:truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 2truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 3Innerscope Research(R) Receives Three Great Minds Innovation Awards from the Advertising Research Foundation 2Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 2Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 3
... (MUC3) is a glycoprotein. distributed in ... extent in breast, lung and salivary gland ... cross-reaction with MUC1 and MUC2. ... Immunogen: MUC3 tandem repeat peptide ...
... bottoms,• Nonreversible lids with ... contamination,• Individual alphanumerical codes ... footprint for ease in ... cell attachment,• Sterilized by ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: